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Outcome measure Evidence Implications
Patient-oriented evidence
Reduction in positive and negative 
symptoms of schizophrenia
Clear As effective as haloperidol and risperidone
Reduction in mood symptoms 
associated with schizophrenia
Clear More effective than haloperidol
Prevention of relapse in stabilized patients Substantial May be fewer relapses than with other atypical 
antipsychotic drugs
Continuing with treatment Substantial Fewer patients may discontinue treatment
Fewer extrapyramidal symptoms than conventional
antipsychotics, similar to other atypical antipsychotics 
Substantial An alternative atypical antipsychotic to avoid the
extrapyramidal symptoms associated with conventional
antipsychotics
No weight gain or metabolic disorders compared 
with other atypical antipsychotics
Moderate The incidence of weight gain is less than for olanzapine
Improves quality of life Moderate May improve quality of life; more evidence needed to confirm
Effective in treatment-resistant schizophrenia No evidence Clozapine still only option
Economic evidence
Cost effectiveness No evidence Apparently similar in cost to other atypical antipsychotics;
higher acquisition cost versus conventional antipsychotics 
may be offset by reduced discontinuation and hospitalization,
but needs to be confirmed
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Abstract
Introduction: An ideal antipsychotic would rapidly stabilize acute psychotic symptoms and maintain the patient, without relapse, 
for prolonged periods in the absence of extrapyramidal, endocrine, diabetic, or cardiovascular side effects, and without weight gain. The
dopamine partial agonist aripiprazole is compared with this ideal and with conventional antipsychotics, such as haloperidol, and with
atypical antipsychotics. 
Aims: To review the evidence for the clinical impact of aripiprazole in the treatment of patients with schizophrenia.
Evidence review: There is clear evidence that aripiprazole is as effective as haloperidol in reducing the positive and negative symptoms
of schizophrenia and schizoaffective disorder. In patients with schizophrenia, aripiprazole has been shown to stabilize acute psychotic
symptoms, prevent relapse in stabilized patients, and maintain patients with schizophrenia following acute relapse. Furthermore, in
common with other atypical antipsychotics, aripiprazole appears to be associated with a lower incidence of side effects than typical
antipsychotics and may reduce discontinuation of drug therapy. Evidence also suggests that aripiprazole may be associated with a lower
incidence of extrapyramidal symptoms than conventional antipsychotics, but further long-term studies concerning tardive dyskinesia are
required. Studies on the cost effectiveness of aripiprazole, as well as the quality of life and general functioning of patients taking the drug
are still required, although there is some evidence of improved quality of life. Further evidence comparing aripiprazole with other atypical
antipsychotics would be welcome.
Clinical value: In conclusion, aripiprazole is an atypical antipsychotic suitable for first-line use in patients with schizophrenia. Its clinical
value in relation to other atypical antipsychotics remains to be elucidated.
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Patients with schizophrenia are often severely debilitated with
disturbed behavior patterns. Currently both atypical and
conventional antipsychotic drugs are used in their treatment.
Atypical antipsychotics are less likely to cause extrapyramidal
symptoms than the conventional antipsychotics. Aytpical
antipsychotics, however, may cause weight gain and the
development of metabolic syndrome and diabetes mellitus, and
have been associated with hyperprolactinemia and QTc
prolongation (Lieberman 2004; Lublin et al. 2005).
The objective of this review is to assess the clinical impact of the
atypical antipsychotic aripiprazole in the treatment and clinical
management of patients with schizophrenia.
Methods
English language searches were conducted on March 31, 2005
and April 1, 2005 using the search terms: “aripiprazole,” “abilify,”
“aripiprazole AND schizophrenia,” and “aripiprazole, schizophrenia
AND clinical trials.” The following sources were searched:
• PubMed, www.ncbi.nlm.gov/entrez, 1966 to date
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluation Database
(NHSEED), Health Technology Assessment (HTA),
www.york.ac.uk/inst/crd/darehp.htm. All three databases were
searched together. All fields searched
• National Guideline Clearinghouse, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk
• Cochrane Database of Systematic Reviews (CDSR),
www.cochrane.org/index0.htm. Entire site searched
• Clinical Evidence (BMJ), www.clinicalevidence.com
• Clinical trial registries, www.clinicaltrials.gov,
www.clinicalstudyresults.org
Continuing automatic searches were carried out through the
National Center for Biotechnology Information (NCBI) until July 19,
2005. A total of 208 articles were retrieved and screened for
relevance (Table 1). Review articles, correspondence, duplicate
publications, and articles not directly related to aripiprazole in
schizophrenia or schizoaffective disorder were excluded from the
analysis. Two additional studies were revealed following hand-
searching. For each outcome, preference was given to level 1 and
level 2 evidence. 
A further search of the English language literature on PubMed
using the search terms “aripiprazole,” “clinical trial,” “meta
analysis,” “randomized controlled trial,” “review,” and “humans”
was conducted with the date limits April 1, 2005 to March 22,
2006. The limits were imposed to provide specificity to the search.
Twenty-six records were found, of which two were included in the
analysis under “additional studies.” Exclusion criteria were the
same as those used in the initial literature searches. A further trial
was revealed manually in this second literature search and was
included in the analysis.
Disease overview
Characteristics of schizophrenia
Schizophrenia is primarily a neurologic disorder externally
observed as disturbed behavior, which is underlain by abnormal
mental and neural functions (Lewis & Lieberman 2000). 
Patients with schizophrenia are often severely debilitated and
lose contact with the real world. The characteristic symptoms of
schizophrenia include two or more of the following, each present
for a significant portion of a 1-month period: delusions;
hallucinations; disorganized speech; grossly disorganized or
catatonic behavior; and/or negative symptoms including flat or
blunted emotions, avolition, limited speech, and general apathy
(Lehman et al. 2004). Symptoms may be divided into three
groups: mild and usually stable; moderate and often stable; and
severe, unstable, and prone to relapse. Early diagnosis is
important to reduce the risk of a full-blown episode already in a
premorbid stage or the risk of an impending relapse, particularly
as schizophrenia is believed to be a neurodevelopmental
disorder in which clinical deterioration may start in the 
premorbid phase (Fig. 1). Patients with schizophrenia exhibit an
increased prevalence of obesity, type 2 diabetes mellitus, and
cardiovascular disease, when compared with the general
population (Newcomer 2004).
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Category Number of records
Full papers Abstracts
Initial search 208 10
records excluded 197 9
records included 11 1
Additional studies identified 5 3
Level 1 clinical evidence 3 0
Level 2 clinical evidence 9 1
Level ≥3 clinical evidence  1 3
trials other than RCT 1
case reports 1
Economic evidence 1 0
For definition of levels of evidence, see Editorial Information on inside back cover.
RCT, randomized controlled trials.
Table 1 | Evidence base included in the review253
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Prevalence of schizophrenia
Schizophrenia affects about 1% of the adult population
worldwide (Clark 2005), but a further 2–3% of the general
population has a milder form of the disease, schizotypal
personality disorder, and do not manifest overtly psychotic
behavior (Kandel 2000; Lewis & Lieberman 2000). The onset of
schizophrenia usually occurs between adolescence and the age
of 40 and may be divided into premorbid, prodromal, and
psychotic phases; the psychotic phase may be subdivided into an
early progressive phase and a later residual phase (Fig. 1). The
age of overt schizophrenic symptoms closely parallel the
reproductive period. 
Burden of illness 
According to Clark (2005), schizophrenia is associated with a
disproportionately large share of the population’s morbidity
because it starts at an early age and is usually progressive, often
with recurrent symptoms. Thus, in most developed countries 8% of
hospital beds are occupied by patients with schizophrenia, many of
whom may be homeless: the weighted average prevalence of
schizophrenia among homeless people is 11% (Folsom & Jeste
2002). Approximately 50% of people with schizophrenia are found
to have had problems with alcohol/substance abuse, and the
disease is statistically associated with male gender and substance
abuse (Folsom et al. 2005). Female patients tend to be older 
than males and are more likely to live independently (Lindamer et al.
2003). The suicide rate among people with schizophrenia is 
20–50 times higher than that of the general population: 10% of
people with schizophrenia commit suicide and 25% attempt it 
(Clark 2005). Furthermore, patients with schizophrenia often suffer
from sexual dysfunction as a result either of the disease itself or as
a side effect of the antipsychotic medications prescribed for them
(Kelly & Conley 2004).
From an economic standpoint, there are arguments for and
against both inpatient and community care for patients. Although
patients with schizophrenia in assisted living facilities make
greater use of outpatient mental health services and have lower
rates of psychiatric and medical hospitalization, their pharmacy
costs and health costs are higher compared with those living
independently or who are homeless (Gilmer et al. 2003). Lien
(2005) suggests that community care is more effective than
hospital-based care, except for the most disabled patients. In
addition the families of patients with schizophrenia experience
both financial and emotional burdens, the extent of which is
related to the amount of symptomatic behavior of the patient
(Lowyck et al. 2004). 
Pathophysiology of schizophrenia 
There is evidence to suggest that schizophrenia has a genetic
basis and runs in families (Kandel 2000; Lewis & Lieberman
2000). Regions on a number of chromosomes have been
identified as sites of potential vulnerability. However,
environmental factors are also thought to play a role in the
pathogenesis of the disease, including exposure to infections,
autoimmune responses, stress during gestation or childhood,
and subtle disorders of brain development and maturation which
do not become apparent until late adolescence and early
adulthood (Fig. 1) (Lewis & Lieberman 2000; Lieberman et al. 2001).
Thus, schizophrenia is likely to be a polygenic disorder in 
which individuals are vulnerable to both developmental and
environmental factors.
Recent studies suggest that specific areas of the genome may
exhibit coinheritance with disease, e.g. specific areas of
chromosome 5p (Cooper-Casey et al. 2005), or that fragile X
syndrome is associated with very early onset schizophrenia
(Vantalon et al. 2005). Owen et al. (2005) indicate that there are
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Fig. 1 | The pathophysiologic course of schizophrenia. Developmental process indicates neuronal maturational processes and
environmental events that may unmask or destabilize vulnerable neural circuits. DA, dopamine; EAA, excitatory amino acids;
Glu, glutamate; NMDA, N-methyl-D-aspartate. Adapted from Lieberman et al. 2001, Biol Psychiatry. 2001;50:884–897 with
permission from the Society of Biological Psychiatryassociations between DNA polymorphisms and schizophrenia
and that the genes most clearly implicated all code for proteins
with a potential impact on the function of glutamate synapses.
These synapses could be the site of primary abnormalities that
disrupt downstream neural circuits; however, this remains to be
demonstrated. In addition, patients with Klinefelter’s syndrome,
which is characterized by an additional X chromosome, are likely
to have structural abnormalities of the amygdala and are at 
an increased risk of schizophrenia (van Rijn et al. 2005). Other
neural structures altered in patients with schizophrenia include
the hippocampus, prefrontal cortex, and dorsal thalamus 
(Owen et al. 2005).
According to Lieberman et al. (2001), the formal onset of
schizophrenia is preceded by significant neurodevelopmental
abnormalities starting in early childhood. Several neurotransmitter
systems appear to be involved including dopaminergic,
serotonergic, gamma-aminobutyric acid (GABA)-ergic, and
glutamatergic neurons (Table 2) (Lieberman 2004). Typical and
atypical antipsychotics are dopamine (D2) receptor antagonists to
some extent. However, atypical antipsychotics bind with other
receptor types, particularly serotonin (5HT2A) receptors, which
may account for the differences in clinical activity compared with
conventional antipsychotics. Antagonism of D2 receptors has
been suggested to account for the effectiveness of both groups
of antipsychotics against the positive symptoms of schizophrenia,
while antagonism of 5HT2A receptors appears to have beneficial
effects on its negative symptoms by indirectly increasing
dopamine synthesis in the prefrontal cortex because 5HT2A
receptor antagonism inhibits serotonin release in the nigrostriatal
and mesolimbic pathways, leading to increased dopaminergic
transmission (Lieberman et al. 1998; Lieberman 2004). Since
atypical antipsychotics interact with several other types of
receptors (Table 2), several other systems of neurons could also
be modulated by them. 
Aripiprazole and bifeprunox are atypical antipsychotics that act as
partial agonists at D2 receptors, although only aripiprazole is
available clinically at present. These agents act as functional
antagonists of dopamine in areas of the brain where excessive
dopamine activity is believed to cause positive symptoms of
schizophrenia, such as the mesolimbic dopamine pathway, while
acting as partial agonists in the mesocortical pathway where
negative symptoms and cognitive impairment are thought to be
associated with reduced levels of dopamine (Lieberman 2004).
Furthermore, D2 partial agonists may avoid blockade of D2
receptors in the nigrostriatal pathway, which could cause
extrapyramidal symptoms (EPS), as well as in the tuberoinfundibular
pathway, which could lead to elevated prolactin levels. 
Current therapy options
The main outcomes of antipsychotic therapy should include
stabilization of acute psychotic symptoms, early rehabilitation,
reduction of the likelihood of relapse, decreased alcohol/substance
abuse, improved quality of life, and reduced family disruption.
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Atypical 
antipsychotic
Receptor binding Other 
pharmacologic
actions
Advantages and disadvantages
Agonist activity Antagonist activity
Amisulpride D2, D3 Acts preferentially on
presynaptic receptors
increasing dopaminergic
transmission at low
doses 
Advantages: quality of life is better than with haloperidol
Disadvantages: insomnia, anxiety, weight gain, dystonia, dose-related EPS,
tardive dyskinesia, hypotension, bradycardia and QT prolongation,
hyperprolactinemia
Clozapine M4 D1–D5, 5HT1A, 5HT2A,
5HT2C, H1, M1, M2,
M4, M5, α1 and α2
adrenergic
NR Advantages: effective in treatment-resistant schizophrenia, no signs of EPS
Disadvantages: sedation, weight gain, high risk of new onset diabetes
Risperidone D1–D4, 5HT1A, 5HT2A,
5HT2C, H1, α1 and α2
adrenergic
NR Advantages: less potential for causing EPS than haloperidol
Disadvantages: insomnia, anxiety, headache, somnolence, dizziness, poor
concentration, sexual dysfunction, weight gain
Olanzapine D1–D4, 5HT2A, 5HT2C,
H1, M1, M2, M4, M5,
α1 adrenergic
NR Advantages: no signs of EPS at lower doses
Disadvantages: sedation, weight gain, high risk of new onset diabetes
Quetiapine D1, D2, 5HT1B/1D,
5HT2A, 5HT2C, H1,
α1 adrenergic
NR Advantages: no signs of EPS
Disadvantages: moderate sedation, some weight gain, risk of new 
onset diabetes
Ziprasidone 5HT1A
a D2, 5HT1A, 5HT2A,
5HT2C, H1, α1
adrenergic
Inhibits neuronal
reuptake of serotonin
and norepinephrine
Advantages: well tolerated
Disadvantages: somnolence, nausea, constipation, dyspepsia, akathisia,
dizziness, diarrhea, QTc prolongation
aPartial agonist activity.
5HT, serotonin; D, dopamine; EPS, extrapyramidal symptoms; H, histamine; M, muscarinic; NR, none relevant reported. 
Table 2 | Summary of the pharmacology, advantages, and disadvantages of currently available atypical antipsychotics255
The primary treatments for schizophrenia are conventional
antipsychotic drugs, often referred to as first-generation
antipsychotics, and atypical antipsychotics, also known as
second-generation antipsychotics. Although conventional
antipsychotics have been demonstrated to be efficacious to
varying degrees, they have been associated with increased rates
of EPS (including acute dystonias and tardive dyskinesia),
increased prolactin secretion (which may be associated with
sexual dysfunction), sedation, hypotension, weight gain, dry
mouth, and blurred vision (Lehman et al. 2004). In general,
atypical antipsychotics are now recommended as the treatment
of choice for patients with schizophrenia because, in comparison
to conventional antipsychotics, they have been associated with a
lower incidence of EPS (Lehman et al. 2004). They have also been
shown to be more efficacious than conventional antipsychotics in
treating the negative symptoms and cognitive dysfunction
associated with schizophrenia. 
Internationally, clinical guidelines agree that atypical
antipsychotics should be considered as first-line medication for
patients in the acute phase of schizophrenia because there is a
decreased risk of EPS and tardive dyskinesia (NICE 2002a;
Lehman et al. 2004; Falkai et al. 2005; RANZCP 2005). They also
state that at present there is no definitive evidence that one
atypical antipsychotic is better than another.
Despite the guideline recommendations, currently available
atypical antipsychotic drugs are not without their drawbacks.
Metabolic disturbance including hyperlipidemia, diabetes, and
excessive weight gain are associated with some of these drugs in
vulnerable individuals (Mortimer 2003; Newcomer 2004), which
may increase the risk of cardiovascular disease in patients treated
with atypical antipsychotics compared with conventional
antipsychotics (Mortimer 2003; Liberty et al. 2004; Lublin et al.
2005). In addition, all of the currently available atypical
antipsychotics have been associated with sedation (Lublin et al.
2005), and some may cause sexual difficulties in both males and
females (Kelly & Conley 2004).
A gap therefore clearly remains between what might be
considered an “ideal” antipsychotic agent and the currently
available options. From a clinical perspective, the ideal agent
would be one that rapidly stabilizes acute psychotic symptoms,
both positive and negative, and maintains the patient without
relapse for prolonged periods in the absence of extrapyramidal,
endocrine, diabetic, or cardiovascular side effects, without weight
gain or sedation. It should also be effective in patients with
treatment resistance symptoms, in whom the only currently
available option is clozapine, which is poorly tolerated (Mortimer,
personal communication).
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Reference Design Treatment 
(no. patients)
Outcomea
PANSS PANSS-P PANSS-N CGI-I CGI-S
Kane et al. 2002 4 w, db,
mc 
Ari 15 mg/d (102)
Ari 30 mg/d (102)
Hal 10 mg/d (104)
Placebo (106)
–15.5 (P<0.001)
–11.4 (P=0.009)
–13.8 (P=0.001)
–2.9
–4.2 (P<0.001)
–3.8 (P=0.001)
–4.4 (P<0.001)
–0.6
–3.6 (P=0.006)
–2.3 (NS)
–2.9 (P=0.043)
–1.2
+3.5 (P<0.001)
+3.8 (P=0.016)
+3.7 (P=0.002)
+4.3
–0.6
–0.4
–0.5
–0.1
Casey et al. 2003 8 w,
open, mc
Ari 30 mg/d
immed disc other
Rx (103)
Ari 30 mg/d taper
off other Rx (104)
Ari 10–30 mg/d
titrate, taper off
other Rx (102)
–7.59
–8.18
–10.11
–1.59
–2.00
–2.75
–2.88
–2.37
–2.81
+3.17
+3.31
+3.16
–0.43
–0.37
–0.39
Pigott et al. 2003 26 w, db,
mc
Ari 15 mg/d (148)
Placebo (149)
–2.08 (P≤0.01)
+4.5
+0.12 (P≤0.01)
+2.37
–1.4
–0.54
+3.74 (P≤0.01)
+4.47
+0.15 (P≤0.05)
+0.4
Potkin et al. 2003 4 w, db,
mc
Ari 20 mg/d (98)
Ari 30 mg/d (96)
Ris 6 mg/d (95)
Placebo (103)
–14.5 (P=0.001)
–13.9 (P=0.003)
–15.7 (P<0.001)
–5.0
–4.9 (P=0.001)
–3.9 (P=0.02)
–5.2 (P<0.001)
–1.8
–3.4 (P=0.002)
–3.4 (P=0.002)
–3.1 (P=0.005)
–0.8
+3.4 (P=0.005)
+3.3 (P=0.001)
+3.3 (P<0.001)
+4.0
–0.5 (P=0.03)
–0.6 (P=0.006)
–0.7 (P<0.001)
–0.2
Tandon et al. 2006 8 w,
open, mc
Ari 10–30 (mean
19.9) mg/d (1255)
Controlb (265)
NR
NR
NR
NR
NR
NR
+2.77
+3.59
NR
NR
aSignificance levels all vs placebo; all results from last-observation-carried-forward (LOCF) analysis.
bZiprasidone (38%), risperidone (20%), quetiapine (19%), olanzapine (12%), clozapine (1%), unspecified typical antipsychotic (7%), unspecified other antipsychotic(s) (3%).
Ari, aripiprazole; CGI-I, Clinical Global Impression—Global Improvement Scale; CGI-S, Clinical Global Impressions—Severity of Illness Scale; d, day; db, double-blind; disc, discontinuation;
Hal, haloperidol; immed, immediate; mc, multicenter; NR, not reported; PANSS, Positive And Negative Syndrome Scale; PANSS-N, Positive And Negative Syndrome Scale—negative
symptoms; PANSS-P, Positive And Negative Syndrome Scale—positive symptoms; Ris, risperidone; Rx, treatment; w, week.
Table 3 | Level 2 evidence of the effects of aripiprazole on schizophrenia and schizoaffective disorder outcomes: 
PANSS and CGI scoresAripiprazole is a partial D2 agonist (Launer 2005; Ohlsen & Pilowsky
2005), but in addition it appears to stabilize dopamine and
serotonin levels (Burris et al. 2002). It is pharmacologically distinct
from the other atypical antipsychotics with partial agonist activity at
both D2 and 5HT1A receptors, and a high affinity for D3, 5HT2A, and
5HT2B receptors (Burris et al. 2002; Jordan et al. 2002; Shapiro et
al. 2003). It also has moderate affinity for D4, 5HT2C, 5HT7, and
alfa1-adrenergic and histamine (H1) receptors (Shapiro et al. 2003).
Aripiprazole is indicated for the treatment of schizophrenia and
acute manic and mixed episodes associated with bipolar disorder. 
Clinical evidence for aripiprazole in schizophrenia
The literature search revealed nine complete randomized
controlled trials (RCTs) on aripiprazole. Attrition rates were
high (34–72%) as previously noted by El-Sayeh and Morganti
(2004). In both long- and short-term studies serious adverse
events were mostly related to the underlying diagnosis,
particularly worsening of psychosis (Marder et al. 2003), to
which many of the discontinuations have been attributed. This
level of discontinuation in trials in patients with schizophrenia
does not appear to be particularly unusual (Mortimer, personal
communication), and has been attributed to placebo-
controlled study design (Kemmler et al. 2005). A number of
abstracts of recent studies are also available; those with
sufficient detail have been included in the analysis, but none
appeared to be RCTs.
Reduction of symptoms of schizophrenia/schizoaffective
disorder 
Reduction in symptoms was the primary endpoint in RCTs of
aripiprazole in patients with schizophrenia, using a number of
scales. The Positive And Negative Syndrome Scale (PANSS)
consists of 30 items on a 7-point scale, and can be used to
assess general psychologic status, and positive and negative
symptoms. A higher score indicates greater severity. The Clinical
Global Impressions—Severity of Illness Scale (CGI-S), and
CGI—Global Improvement Scale (CGI-I) assess severity of illness
and clinical improvement, with higher scores on a 7-point scale
again indicating worsening of illness. 
There is strong evidence that aripiprazole was effective in reducing
the symptoms of schizophrenia and schizoaffective disorder at
daily doses of 15–30 mg/day (Table 3). Both positive and negative
symptoms were reduced, and aripiprazole was at least as effective
as risperidone and haloperidol. Significantly greater efficacy
(P<0.05) for aripiprazole against negative symptoms compared
with haloperidol was reported in one study involving 495 patients
(Kasper et al. 2003). Onset of action of aripiprazole was rapid, with
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Reference Design Response criteria Treatment (no. patients) Response rate (%)a
Kane et al.
2002
4 w, db,
mc
CGI-I score 1 or 2, or ≥30% decrease 
from baseline in PANSS score
Ari 15 mg/d (102)
Ari 30 mg/d (102)
Hal 10 mg/d (104)
Placebo (106)
35 (P=0.002)
28 (P=0.05)
26
17
Potkin et al.
2003
4 w, db,
mc
CGI-I score 1 or 2, or ≥30% decrease 
from baseline in PANSS score
Ari 20 mg/d (98)
Ari 30 mg/d (96)
Ris 6 mg/d (95)
Placebo (103)
36 (P=0.04)
41 (P=0.005)
40 (P=0.008)
23
Kasper et al.
2003
52 w, db,
mc
≥20% decrease from baseline in PANSS 
score at any single time point, without 
CGI-I score of 6 or 7, adverse event of
worsening schizophrenia, or a score of 
5, 6, or 7 on at least one of the four 
PANSS psychotic subscale items
Ari 30 mg/d (853)
Hal 10 mg/d (430)
72
69
≥30% decrease from baseline in PANSS 
score maintained for at least 28 d, without 
CGI-I score of 6 or 7, adverse event of
worsening schizophrenia, or a score of 
5, 6, or 7 on at least one of the four 
PANSS psychotic subscale items
Ari 30 mg/d (853)
Hal 10 mg/d (430)
52 (P<0.003 vs Hal)
44
McQuade et
al. 2004
26 w, db,
mc
CGI-I score 1 or 2 Ari 25.1 mg/d (mean) (156)
Ola 16.5 mg/d (mean) (161)
61
62
Tandon et al.
2006
8 w, open,
mc
CGI-I score 1 or 2 Ari 10–30 (mean 19.9) mg/d (1255)
Controlb (265)
54
31
aSignificance levels all vs placebo except where stated; all results from last observation carried forward analysis.
bZiprasidone (38%), risperidone (20%), quetiapine (19%), olanzapine (12%), clozapine (1%), unspecified typical antipsychotic (7%), unspecified other antipsychotic(s) (3%).
Ari, aripiprazole; CGI-I, Clinical Global Impressions—Global Improvement Scale; d, day; db, double-blind; Hal, haloperidol; mc, multicenter; Ola, olanzapine; PANSS, Positive and Negative
Syndrome Scale; Ris, risperidone; w, week.
Table 4 | Level 2 evidence of response rates to aripiprazole in patients with schizophrenia or schizoaffective disorder257
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symptom scores decreasing significantly within 2 weeks of
initiating treatment, and was maintained for up to 52 weeks
(Kasper et al. 2003). A post-hoc pooled analysis of five short-term
studies (4 to 6 weeks) demonstrated that aripiprazole was
significantly more effective than placebo and comparable to
haloperidol in alleviating hostility in patients with schizophrenia or
schizoaffective disorder (Volavka et al. 2005). 
The evidence for the efficacy of aripiprazole is strong both in
patients experiencing an acute relapse (Kane et al. 2002; Kasper
et al. 2003; Potkin et al. 2003), and in patients with chronic stable
disease (Casey et al. 2003; Pigott et al. 2003), in whom consistent
and progressive symptom improvement has been reported for up
to 8 weeks (Casey et al. 2003). 
Reduction in mood symptoms associated 
with schizophrenia
Mood symptoms, particularly schizophrenia-associated depression
and anxiety, are an important consideration in the management of
patients with schizophrenia. The effect of aripiprazole on these
symptoms has been assessed as a secondary endpoint. There is
evidence that aripiprazole is significantly more effective than
placebo (P=0.001) (Carson et al. 2003) and haloperidol (P<0.05)
(Carson et al. 2003; Kasper et al. 2003) in improving depressive
symptoms as assessed by factor analysis of PANSS scores or by
the Montgomery–Asberg Depression Rating Scale. The effect of
aripiprazole was significant at 4 to 6 weeks (Carson et al. 2003),
and was maintained for up to 52 weeks (Kasper et al. 2003).
Prevention of relapse in stabilized patients
There is evidence from one randomized, double-blind, multicenter trial
that aripiprazole is less frequently associated with relapse compared
with placebo in patients with chronic stable schizophrenia [Diagnostic
and Statistical Manual of Mental Disorders—Fourth Edition (DSM-IV)
criteria] (Pigott et al. 2003). In 297 evaluable patients, time to relapse
was significantly longer (P<0.001) in the group receiving aripiprazole
15 mg/day compared with placebo, and fewer patients relapsed (34
vs 57%) after 26 weeks. As a measure of efficacy, the relative risk (RR)
of relapse for aripiprazole compared with placebo was calculated as
0.59 [95% confidence interval (CI) 0.45, 0.75; P<0.001]. This study
used relapse criteria which were more stringent than those defined in
previous studies with atypical antipsychotic therapy, and represent a
deterioration rather than a specific event (El-Sayeh & Morganti 2004).
Response rate
An alternative to clozapine to overcome treatment resistance is a
major unmet need in the management of patients with
schizophrenia. Five studies provide evidence of the response rate
to aripiprazole, using various combinations of symptom score
reductions (Table 4). All patients in these studies were
experiencing acute relapse of schizophrenia, and had previously
responded to antipsychotic medication other than clozapine 
(i.e. they were not treatment resistant).
Response to aripiprazole 15–30 mg/day was significantly greater
than for placebo, and comparable to risperidone 6 mg/day 
(Potkin et al. 2003) and haloperidol 10 mg/day after 4 weeks
(Kane et al. 2002). However, in the longer term more patients
appear to respond to aripiprazole than to haloperidol. After 
52 weeks, response rates (defined as ≥30% decrease from
baseline in PANSS score maintained for at least 28 days, without
CGI-I score of 6 or 7, adverse event of worsening schizophrenia,
or a score of 5, 6, or 7 on at least one of the four PANSS psychotic
subscale items) to aripiprazole compared with haloperidol were
52 vs 44% (P<0.003), and proportion of patients failing to
Treatment (no. patients) Number of patients leaving study early (%)
Any reason Adverse effects
Aripiprazole vs placebo (6 RCTs)
Aripiprazole (n=1087) 477 (44%) 66 (6%)
Placebo (n=571) 345 (60%) 43 (8%)
Relative risk [confidence interval] 0.68 [0.55, 0.86] 0.82 [0.40, 1.70]
Aripiprazole vs typical antipsychotics (5 RCTs)
Aripiprazole (n=1433) 691 (48%) 118 (8%)
Typical antipsychotics (n=780) 419 (54%) 110 (14%)
Relative risk [confidence interval] 0.90 [0.76, 1.05] 0.77 [0.37, 1.60]
Aripiprazole vs atypical antipsychotics (2 RCTs)
Aripiprazole (n=358) 191 (53%) 18 (5%)
Atypical antipsychotics (n=260) 150 (58%) 21 (8%)
Relative risk [confidence interval] 1.05 [0.93, 1.19] 0.78 [0.42, 1.42]
RCT, randomized controlled trial.
Table 5 | Level 1 evidence (meta analysis within a systematic review) of aripiprazole discontinuation in patients with schizophrenia or
schizoaffective disorder (El-Sayeh & Morganti 2004)maintain a response at week 52 was 85 vs 79% (RR 0.70; 95% CI
0.45, 1.07; P=0.098) (Kasper et al. 2003).
Reduced discontinuation rates
There is a solid body of evidence that fewer patients taking
aripiprazole discontinue treatment. This evidence comprises a
meta analysis of RCTs (level 1 evidence), as well as level 3
evidence from a large database of patients with schizophrenia or
schizoaffective disorder. 
The level 1 evidence indicates that significantly fewer patients
taking aripiprazole left the study early compared with those taking
placebo, typical antipsychotics, or atypical antipsychotics
(Table 5). Nevertheless, approximately half of all aripiprazole
recipients did not complete the full course of study treatment,
calling the results into question. Similar discontinuation rates in
trials in patients with schizophrenia are not uncommon (Mortimer,
personal communication). Adverse events do not appear to be
the cause of this attrition rate (El-Sayeh & Morganti 2004).
Table 6 shows the reasons reported for treatment discontinuation
in RCTs of aripiprazole in patients with schizophrenia and
schizoaffective disorder. Worsening of illness and insufficient
clinical response was often just as, or more, likely to be the cause
of discontinuing aripiprazole as adverse events. With the
exception of the study by Pigott et al. (2003), other reasons were
the commonest cause of stopping treatment, usually related to
violation of or noncompliance with study design, and applying to
all study groups.
Level 3 evidence from a database of 2947 patients with
schizophrenia or schizoaffective disorder demonstrated that
aripiprazole-treated patients exhibited the lowest risk for
discontinuation [hazard ratio (HR) 0.60; 95% CI 0.50, 0.72]
compared with conventional antipsychotics and the atypical
antipsychotics quetiapine (HR 0.67; 95% CI 0.56, 0.80),
ziprasidone (HR 0.74; 95% CI 0.60, 0.91), risperidone (HR 0.79;
95% CI 0.67, 0.95), and olanzapine (HR 0.83; 95% CI 0.70, 0.99)
(Olfson et al. 2005b).
Likewise, the risk of rehospitalization in a database of 576
patients was significantly lower for aripiprazole (HR 0.27; 95% CI
0.08, 0.91) and olanzapine (HR 0.41; 95% CI 0.20, 0.84)
compared with typical antipsychotics (Carrigan et al. 2005), but
was not significantly lower for risperidone (HR 0.53; 95% CI 0.27,
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Reference Design Treatment 
(no. patients)
Reason for discontinuation, proportion of patients (%) Total patients
discontinued (%)a
Insufficient clinical
response/lack of
efficacy (relapse)
Worsening
schizophreniab
Adverse events Otherc
Kane et al. 
2002
4 w, db, mc  Ari 15 mg/d (102)
Ari 30 mg/d (102)
Hal 10 mg/d (104)
Placebo (106)
5
15
6
14
NR
NR
NR
NR
9
8
11
16
20
19
24
15
33
41
40
45
Casey et al. 
2003
8 w, open, mc Ari 30 mg/d immed
disc other Rx (104)
Ari 30 mg/d taper
off other Rx (104)
Ari 10–30 mg/d
titrate, taper off
other Rx (103)
NR
NR
NR
10
10
8
6
10
6
15
14
6
31
34
19
Kasper et al.
2003
52 w, db, mc Ari 30 mg/d (861)
Hal 10 mg/d (433)
7
9
17
13
8
19
25
30
57
70
Pigott et al. 
2003
26 w, db, mc Ari 15 mg/d (155)
Placebo (155)
27d
49d
NR
NR
10
8
17e
14
54
71
Potkin et al. 
2003
4 w, db, mc Ari 20 mg/d (101)
Ari 30 mg/d (101)
Ris 6 mg/d (99)
Placebo (103)
9
8
8
17
NR
NR
NR
NR
11
8
8
17
20
18
21
17
40
34
37
50
Tandon et al.
2006
8 w, open, mc Ari 10–30 (mean
19.9) mg/d (1255)
Controlf (265)
3.8
7.6
NR
NR
17
11.5
5.9
13.2
35
43
aIndividual numbers in each column may not add up to total due to rounding.
bDefined by the modified COSTART dictionary terms “psychosis” and “schizophrenic reaction”; the majority of these events represent a relapse of the primary disease and are not considered
attributable to study medication (Kasper et al. 2003). Not defined for Casey et al. 2003.
cOther known causes included lost to follow-up, patient withdrew consent, patient met withdrawal criteria, study participation terminated by sponsor, protocol violation, laboratory
abnormalities, positive cannabinoid screening, anemia, randomization error, and noncompliance.
dLack of efficacy (relapse) stated as a reason for discontinuation.
eIncludes one death.
fZiprasidone (38%), risperidone (20%), quetiapine (19%), olanzapine (12%), clozapine (1%), unspecified typical antipsychotic (7%), unspecified other antipsychotic(s) (3%).
Ari, aripiprazole; COSTART, Coding Symbols for Thesaurus of Adverse Reaction Terms; d, day; db, double-blind; disc, discontinuation; Hal, haloperidol; immed, immediate; mc, multicenter; 
NR, not reported; RCT, randomized controlled trial; Ris, risperidone; Rx, treatment; w, week.
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1.05), quetiapine (HR 0.63; 95% CI 0.31, 1.27), and ziprasidone
(HR 0.76; 95% CI 0.37, 1.58). 
Safety and tolerability of aripiprazole
Table 7 shows the level 1 evidence of the adverse
effects encountered during trials with aripiprazole in patients
with schizophrenia and schizoaffective disorder (El-Sayeh &
Morganti 2004).
The incidence of anxiety, headache, insomnia, and nausea was
similar in patients receiving aripiprazole or placebo (Table 7).
Compared with the typical antipsychotic perphenazine,
aripiprazole was associated with a greater frequency of
insomnia and dyspepsia, although this was not significant
(El-Sayeh & Morganti 2004). Similarly, in a 4-week study,
nausea was more frequent in patients taking aripiprazole 15 or
30 mg/day (15 and 14%, respectively) compared with those
receiving haloperidol 10 mg/day (6%), as was dizziness (13 and
17 vs 6%) (Kane et al. 2002). Nausea was mild and transient in
nature, resolving within 1 week. The incidence of insomnia was
similar in all patients (19 and 22 vs 24%), but somnolence was
more common in those taking haloperidol (5 and 10 vs 13%). In
a longer-term study, the incidence of headache, anxiety,
insomnia, and somnolence did not differ between aripiprazole
or haloperidol after 52 weeks’ treatment (Kasper et al. 2003).
Compared with the atypical antipsychotics risperidone 
and olanzapine, aripiprazole was associated with a greater
frequency of anxiety, headache, insomnia, and nausea, but not
significantly (Table 7). 
There is level 2 evidence of a similar safety and tolerability profile 
for aripiprazole in real-world practice settings. Adverse events
reported by ≥5% of 1255 aripiprazole recipients in a multicenter,
prospective, open-label study included insomnia (24%), nausea
(16%), headache (11%), anxiety (10%), somnolence (8%), agitation
(7%), lightheadedness (6%), diarrhea (6%), vomiting (5%), and
psychosis (5%) (Tandon et al. 2006). 
Extrapyramidal symptoms
Level 1 evidence from RCTs indicates that there was no
significant difference in the occurrence of EPS, including akathisia
and need for antiparkinsonian medication, in patients treated with
aripiprazole or placebo (15 vs 8%) (El-Sayeh & Morganti 2004).
There is also level 1 evidence that the need for antiparkinsonian
treatment was significantly reduced in aripiprazole recipients
compared with those taking a typical antipsychotic (22 vs 51%;
RR 0.45; 95% CI 0.33, 0.6) (El-Sayeh & Morganti 2004), although
the incidence of akathisia and general EPS was not significantly
different. This may be because that there were too few studies
and hence too little power to detect a difference (El-Sayeh &
Morganti 2004).
Indeed, level 2 evidence does indicate a lower frequency of 
EPS in aripiprazole recipients compared with the typical
antipsychotic haloperidol (Table 8). The evidence also suggests
a similar rate of EPS with aripiprazole compared with the
atypical antipsychotics risperidone and olanzapine (Potkin et al.
2003; El-Sayeh & Morganti 2004; McQuade et al. 2004).
In studies on patients following acute relapse, symptoms of EPS
were observed with similar frequency in patients treated with
aripiprazole 15–30 mg/day (17%) and olanzapine 10–20 mg/day
(16%) (McQuade et al. 2004) after 26 weeks, and after 52 weeks
aripiprazole 30 mg/day was associated with significantly lower
EPS assessments (10%) than haloperidol 10 mg/day (30%;
P<0.001) (Kasper et al. 2003). 
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Treatment (no. patients) Number of patients with adverse effects (%)
Anxiety Headache Insomnia Nausea/dyspepsia
Aripiprazole vs placebo (2 RCTs)
Aripiprazole (n=357)
Placebo (n=258)
Relative risk [CI]
64 (18%)
53 (20%)
0.86 [0.53, 1.39]
80 (22%)
49 (19%)
1.04 [0.76, 1.43]
120 (34%)
86 (33%)
1.09 [0.87, 1.37]
27 (7%)
17 (6%)
1.05 [0.59, 1.88]
Aripiprazole vs typical 
antipsychotics (1 RCT)
Aripiprazole (n=154)
Typical antipsychoticsa (n=146)
Relative risk [CI]
17 (11%)
19 (13%)
0.85 [0.46, 1.57]
9 (6%)
13 (9%)
0.66 [0.29, 1.49]
73 (47%)
31 (21%)
2.23 [1.57, 3.18]
17 (11%)
9 (6%)
1.79 [0.82, 3.89]
Aripiprazole vs atypical
antipsychotics (2 RCTs)
Aripiprazole (n=330)
Atypical antipsychotics (n=226)
Relative risk [CI]
64 (19%)
23 (10%)
2.1 [0.56, 7.96]
86 (26%)
48 (21%)
1.08 [0.8, 1.46]
95 (29%)
34 (15%)
1.93 [0.89, 4.17]
41 (12%)
20 (9%)
1.43 [0.38, 5.44]
aPerphenazine.
CI, confidence interval; RCT, randomized controlled trial.
Table 7 | Level 1 evidence (meta analysis within a systematic review) of incidence of adverse effects with aripiprazole in patients
with schizophrenia or schizoaffective disorder (El-Sayeh & Morganti 2004)In longer-term studies, psychosis, akathisia, tremor, and
somnolence do appear as common adverse effects (Kasper et al.
2003; Pigott et al. 2003; McQuade et al. 2004), suggesting 
that evidence from long-term clinical use of aripiprazole would 
be welcome, including the potential for development of 
tardive dyskinesia. The issue of akathisia is interesting since,
although reported in long-term studies, akathisia or agitation 
may also occur after short-term use of aripiprazole (Möller,
personal communication).
Metabolic risk 
Level 1 and 2 evidence indicates that aripiprazole was more frequently
associated with weight gain than placebo, but not to a significant
extent (Table 9) (El-Sayeh & Morganti 2004). Compared with placebo,
aripiprazole was not associated with any clinically significant change
in fasting glucose, glycosylated hemoglobin, total low-density
lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, and
triglycerides (Pigott et al. 2003; El-Sayeh & Morganti 2004). 
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Reference Design Treatment 
(no. patients, safety
population)
Outcome
Patients experiencing
EPS-related events (%)
SAS/Barnes Akathisia 
Rating Scale/AIMS
Patients requiring
concomitant 
anticholinergic 
treatment (%)
Kane et al. 2002 4 w, db, mc  Ari 15 mg/d (102)
Ari 30 mg/d (101)
Hal 10 mg/d (103)
Placebo (104)
18
20
36
21
No significant changes in scores
with Ari compared with placebo.
8
15
30
12
Casey et al. 2003 8 w, open, mc Ari 30 mg/d immed disc
other Rx (103)
Ari 30 mg/d taper off 
other Rx (104)
Ari 10–30 mg/d titrate, 
taper off other Rx (102)
15a
11a
21a
An evaluation of mean 
changes from baseline showed
no worsening or mild
improvement in all treatment
groups throughout the duration
of the study
2
4
7
Kasper et al. 2003 52 w, db, mc Ari 30 mg/d (851)
Hal 10 mg/d (428)
27
58
Ari was associated with
significantly less abnormal
involuntary movement than Hal
throughout the duration of the
study as measured by changes
from baseline for all scales 
(all P<0.0001 vs Hal)
23
57
Pigott et al. 2003 26 w, db, mc Ari 15 mg/d (153)
Placebo (153)
20
13
Ari use associated with a
significantly greater improvement
from baseline to endpoint in SAS
score compared with placebo
(–0.83 vs –0.44 respectively;
P≤0.05). No significant changes
in Barnes Akathisia Rating Scale
or AIMS scores with Ari
compared with placebo
14
12
Potkin et al. 2003 4 w, db, mc Ari 20 mg/d (101)
Ari 30 mg/d (100)
Ris 6 mg/d (99)
Placebo (103)
32
31
31
20
No significant differences between
Ari/Ris and placebo for SAS or
Barnes Akathisia Rating Scale
scores. Only Ris produced a
significant change in AIMS score
compared with placebo (P=0.03)
Comparable across all
treatment groups 
(data not provided)
McQuade et al. 2004  26 w, db, mc Ari 25.1 mg/d (mean) (153)b
Ola 16.5 mg/d (mean) (156)b
17
16
NR Overall, 15% of patients
received treatment
Tandon et al. 2006 8 w, open, mc Ari 10–30 (mean 19.9) 
mg/d (1255)
Controlc (265)
10
8
3.3
3.4
aNumber of akathisia events only.
bCalculated from stated incidence data.
cZiprasidone (38%), risperidone (20%), quetiapine (19%), olanzapine (12%), clozapine (1%), unspecified typical antipsychotic (7%), unspecified other antipsychotic(s) (3%). 
AIMS, Abnormal Involuntary Movement Scale; Ari, aripiprazole; d, day; db, double-blind; disc, discontinuation; Hal, haloperidol; immed, immediate; mc, multicenter; NR, not reported;
Ola, olanzapine; Ris, risperidone; Rx, treatment; SAS, Simpson–Angus Scale; w, week.
Table 8 | Level 2 evidence of incidence of extrapyramidal symptoms with aripiprazole in patients with schizophrenia or
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The incidence of weight gain was lower with aripiprazole and
haloperidol in a 4-week study (Kane et al. 2002), although over
52 weeks the mean change in body weight was greater (not
significant) following aripiprazole 30 mg/day compared with
haloperidol 10 mg/day (Kasper et al. 2003). Aripiprazole was
associated with a significantly greater increase in weight gain
compared with haloperidol in patients with the lowest body mass
index (<23 kg/m2). 
Body weight gain was comparable in patients receiving aripiprazole
20 or 30 mg/day or risperidone 6 mg/day after  4 weeks (Potkin et
al. 2003). However, a 26-week RCT by McQuade et al. (2004)
showed that by the end of the trial, 37% of patients with acute
relapse treated with a mean dose of olanzapine 16.5 mg/day
(n=161) experienced significant weight gain compared with 14% of
those treated with a mean dose of aripiprazole 25.1 mg/day
(P<0.001) (n=156). This observation is further supported by a meta
analysis showing that aripiprazole, amisulpride, and ziprasidone
were associated with only modest weight gain (<2 kg), while
olanzapine was associated with clinically significant weight
increases (4–10 kg) (Newcomer 2004), and by a short retrospective
study on 10 elderly patients (Madhusoodanan et al. 2004).
After 26 weeks, triglyceride (P<0.05), total cholesterol, and LDL
cholesterol levels were lower in patients receiving aripiprazole
15–30 mg/day compared with those receiving olanzapine 
10–20 mg/day, and HDL cholesterols were higher (P<0.05)
(McQuade et al. 2004). Significantly fewer of the aripiprazole
group had clinically significant dyslipidemias compared with the
olanzapine group (P<0.05).
A further case–control study indicated that aripiprazole-treated
patients had a similar risk of developing hyperlipidemia compared
with patients treated with conventional antipsychotics [odds ratio
(OR) 0.80; 95% CI 0.60, 1.07] or with ziprasidone (OR 0.97;
95% CI 0.84, 1.12) (Olfson et al. 2005a). In contrast, clozapine,
quetiapine, risiperidone, and olanzapine were each associated
with a significantly greater risk of hyperlipidemia compared with
conventional agents. 
There has recently been some discussion about an increased risk of
cerebrovascular adverse events with atypical antipsychotics in
elderly patients with dementia-related psychosis (Schneider et al.
2005). In February 2005, the US prescribing information for
aripiprazole added a warning of the possibility of increased
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Reference Design Treatment 
(no. patients, 
safety population)
Outcome
Mean change from
baseline in body
weight (kg)
Percentage of patients
with significant weight
gain at endpoint (≥7%
increase from baseline) 
Mean change from
baseline in serum
prolactin levels 
(ng/mL)
Patients with 
prolactin levels 
>ULN
Kane et al.
2002
4 w, db, mc  Ari 15 mg/d (102)
Ari 30 mg/d (102)
Hal 10 mg/d (104)
Placebo (106)
+0.4
+0.9
+0.5
+0.2
7%
4%
10%
1%
–7.0 
–7.1
+22.5 
–1.8
NR
NR
NR
NR
Casey et al.
2003
8 w, open, mc Ari 30 mg/d immed
disc other Rx (103)
Ari 30 mg/d taper
off other Rx (104)
Ari 10–30 mg/d
titrate, taper off
other Rx (102)
–1.4
–1.7
–1.3
3%
5%
3%
–15.9
–19.4
–16.2 
1 patient
4 patients
8 patients 
Kasper et al.
2003
52 w, db, mc Ari 30 mg/d (839)
Hal 10 mg/d (425)
+1.05
+0.39
NR
NR
-8.1 (n=96)a
+34.2 (n=46)a
3.4% (n=96)a
61% (n=46)a
Pigott et al.
2003
26 w, db, mc Ari 15 mg/d (151)
Placebo (151)
–1.26
–0.87
6%
4%
–21 
–13 
5%
13%
Potkin et al.
2003
4 w, db, mc Ari 20 mg/d (101)
Ari 30 mg/d (101)
Ris 6 mg/d (99)
Placebo (103)
+1.2
+0.8
+1.5
–0.3
13%
9%
11%
2%
–6.6 
–6.4 
+47.9 
+0.1
4.1%
3.3%
90.5%
10.3%
McQuade et al.
2004 
26 w, db, mc Ari 25.1 mg/d
(mean) (154) 
Ola 16.5 mg/d
(mean) (155)
–1.37
+4.23
13%
33%
NR
NR
8%
37%
aSerum prolactin levels were only collected in the first (USA study) of the two combined studies.
bFor patients with prolactin levels within ULN at baseline only.
Ari, aripiprazole; d, day; db, double-blind; disc, discontinued; Hal, haloperidol; immed, immediate; mc, multicenter; NR, not reported; ola, olanzapine; Ris, risperidone; Rx, treatment;
ULN, upper limit of normal; w, week.
Table 9 | Level 2 evidence of the changes in body weight and serum prolactin levels with aripiprazole in patients with schizophrenia
or schizoaffective disordercerebrovascular risk in these patients (Anon. 2005). Level 1 evidence
from a meta analysis indicates an OR of 1.73 (95% CI 0.7, 4.3) and
RR 1.99 (95% CI 0.86, 4.62) for death with aripiprazole in patients
with dementia (Schneider et al. 2005). In this patient population, the
small increased risk associated with aripiprazole treatment of 8–12
weeks is in common with the other atypical antipsychotic drugs
olanzapine, quetiapine, and risperidone.
Prolactin levels
There is consistent level 2 evidence that aripiprazole is associated
with decreases in prolactin levels, in contrast to haloperidol,
risperidone, and olanzapine, all of which were associated with
increases (Table 9). 
QTc interval
A 20-day, placebo-controlled, double-blind study in 50 healthy
male volunteers revealed that aripiprazole 5–30 mg/day induced
no clinically significant changes in QTc (Mallikaarjun et al. 2004). 
In patients with schizophrenia and schizoaffective disorder, Potkin
et al. (2003) found mean changes in QTc interval of +0.97, –2.35,
–2.18, and +6.31 msec with aripiprazole 20 mg/day, aripiprazole
30 mg/day, placebo, and risperidone 6 mg/day, respectively.
A clinically significant increase in QTc interval (QTc of ≥450 msec
and ≥10% increase from baseline) occurred in three of the
95 risperidone recipients, but not in any other group.
Switching to aripiprazole from other antipsychotic agents
According to Casey et al. (2003), switching antipsychotic
medications can lead to tolerability problems. In an 8-week,
randomized, open-label RCT three possible strategies were
adopted to switch 311 patients to aripiprazole 30 mg/day from
typical antipsychotics (haloperidol or thioridazine) or atypical
antipsychotics (risiperidone or olanzapine). The switching process
was safe and well tolerated whether patients were switched
immediately to aripiprazole with immediate discontinuation of the
previous antipsychotic, switched immediately to aripiprazole
while tapering off the previous antipsychotic over a 2-week
period, or tapered gradually onto aripiprazole while tapering off
the previous antipsychotic over 2 weeks (Casey et al. 2003). 
After 8 weeks, patients switched to aripiprazole showed
improvements in EPS, reductions in prolactin levels and weight,
and significant improvements in PANSS scores. Nevertheless,
there is some conflicting evidence from a case series report that
four patients switched to aripiprazole 15–30 mg/day experienced
worsening of psychosis which improved in two of the 
patients when aripiprazole therapy was discontinued
(Ramaswamy et al. 2004). 
Quality of life
Although quality of life is important for patients with
schizophrenia, it is difficult to determine due to the fact that it
relies on patient perception and self-evaluation, which is likely to
be impaired by the underlying condition. 
Evidence on the effect of aripiprazole on quality of life is limited.
Unpublished data from an RCT reported in the systematic review
by El-Sayeh and Morganti (2004) revealed no conclusive evidence
of a clinically important improvement in quality of life among 
154 patients given aripiprazole, as assessed by the Quality of Life
Scale, a measure specific for schizophrenic deficit syndrome or
enduring negative symptoms. 
A prospective, multicenter, randomized, open-label study
provides stronger evidence for a beneficial effect of aripiprazole
on quality of life (Tandon et al. 2006). Approximately 71% of 
1214 evaluable patients receiving a mean dose of aripiprazole
19.9 mg/day, and 60% of their caregivers rated the drug as better
or much better than prestudy medication, compared with 49% of
patients and 38% of caregivers in the active control group. 
Further evidence for a positive effect of aripiprazole on quality of
life comes from an abstract report of an open-label, prospective,
randomized study in 1119 outpatients with schizophrenia who
switched to aripiprazole or another antipsychotic (olanzapine,
risperidone, quetiapine, ziprasidone, or unspecified) (Carson et al.
2004). Using a 5-point scale, 60% of patients previously on
ziprasidone, 53% on an unspecificied typical antipsychotic, 50%
on olanzapine, 49% on quetiapine, 49% on more than one other
antipsychotic, and 48% on risperidone preferred aripiprazole.
Between 34 and 45% of caregivers classified aripiprazole as
“much better” than the previous medication. 
Economic evidence
No formal studies on the cost effectiveness of aripiprazole have
been reported. However, although doses compared did not imply
therapeutic equivalence, cost comparisons in the UK conducted
in 2004 revealed that the cost for 28 days’ treatment with
aripiprazole 10 or 15 mg/day (£101.63) was approximately the
same as olanzapine 10 mg/day (£97.56), and risperidone 
6 mg/day (£109.20) (Anon. 2004a; Chapman 2004). Aripiprazole
30 mg/day costs £203.26 for 28 days, comparable to the £195.11
for olanzapine 20 mg/day (Anon. 2004a). Twenty-eight days’
treatment with haloperidol 10 or 20 mg/day costs up to £11.99
(Anon. 2004a), or £86–156 for 1 year (Anon. 2004b). 
Resource utilization
Despite the higher acquisition cost of aripiprazole compared with
haloperidol, this might be offset by the reduced discontinuation
(Olfson et al. 2005b) and hospitalization rates (Carrigan et al.
2005), and better tolerability. Indeed, NICE guidance in England
and Wales recommending the first-line use of atypical
antipsychotics to manage schizophrenia in various primary and
secondary care settings recognized the overall indirect cost
benefits (e.g. more patients living independently and returning to
work) and better tolerability compared with typical antipsychotics
(NICE 2002a,b). NICE reported an estimated average cost saving
of £1000 (£250–5000) per patient year in switching to atypical
antipsychotics (NICE 2002a), and although aripiprazole was not
available in the UK at the time guidance was issued, the clinical
evidence suggest that it too could result in similar cost savings. 
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Patient group/population
Studies to date suggest that atypical agents such as aripiprazole
should be considered as first-line treatment of choice for patients
newly diagnosed with schizophrenia or for patients suffering
unacceptable adverse events with conventional agents (NICE
2002a; Chapman 2004). Switching to aripiprazole from other
atypical antipsychotic drugs or from conventional antipsychotics
appears to be well tolerated in most cases (Casey et al. 2003).
The choice of which atypical antipsychotic depends on local
acquisition costs, and on individual response and tolerability to
other agents. Specific consensus guidelines for the use of
aripiprazole in schizophrenia have recently been published by the
Schizophrenia Innovation Working Group in the UK (Travis et al.
2005). They suggest that in comparison with other available
antipsychotics, aripiprazole may be a useful alternative for
patients for whom weight gain, EPS, and sedation are barriers to
long-term treatment. Prescribing information carries a warning of
increased cerebrovascular events in elderly patients with
dementia-related psychosis (Anon. 2005).
Dosage, administration, and formulations
Aripiprazole (Abilify®, Bristol-Myers Squibb) is available as 2, 5,
10, 20, and 30 mg tablets and as a 1 mg/mL solution for oral
administration. The recommended starting dose is 10 or 15 mg
once daily, with maintenance of 15 mg/day; dosage should not be
increased in the first 2 weeks of treatment, and the maximum
recommended daily dose is 30 mg (Anon. 2005). Dosage
adjustment is not required in patients with impaired renal or
hepatic function.
Clinical value
Atypical antipsychotics are now recommended as first-line agents
for the treatment of patients with schizophrenia. Aripiprazole is a
recent addition to the available atypical antipsychotics.
There is evidence that aripiprazole is at least as effective as
haloperidol against the positive and negative symptoms of
schizophrenia (Kane et al. 2002; Kasper et al. 2003), more
effective in ameliorating the associated mood symptoms (Kasper
et al. 2003), and is associated with a lower incidence of adverse
events, particularly EPS. Aripiprazole also appears as effective as
other atypical antipsychotics in the treatment of the positive and
negative symptoms of schizophrenia. It has a relatively benign
adverse event profile, comparable to that of other atypical
antipsychotics. Importantly, aripiprazole is not associated with an
increased risk of weight gain, metabolic disturbances, or
increases in prolactin levels. This favorable tolerability profile may
enhance compliance. Further observational studies, and evidence
on cost effectiveness and resource utilization, and on the patient-
oriented outcomes of quality of life, general functioning, and
satisfaction with treatment would help with defining the place in
therapy of aripiprazole (El-Sayeh & Morganti 2004), especially
compared with other atypical antipsychotics. Also, although EPS
is less common with aripiprazole, tremor and akathisia have been
reported in longer-term studies (Kasper et al. 2003; Pigott et al.
2003; McQuade et al. 2004), suggesting a need for more evidence
from long-term clinical use on the potential for development of
tardive dyskinesia with aripiprazole.
Another issue of particular interest is that of treatment resistance.
This remains a major unmet need, with clozapine being the only
option despite its poor tolerability profile. There is no evidence
that aripiprazole is effective in treatment-resistant patients.
Interestingly, however, despite substantial numbers of patients
leaving trials, fewer patients on aripiprazole discontinued
treatment compared with other antipsychotics, either due to
insufficient clinical response, worsening of illness, or adverse
effects. Not only were discontinuation rates lower for aripiprazole
in controlled trials, where treatment-resistant patients were
excluded, but also in observational studies. A recent large-scale
prospective effectiveness study in general psychiatry outpatient
practice settings confirmed this finding, with a lower proportion of
discontinuations among aripiprazole recipients than with active
controls (Tandon et al. 2006). This is a telling observation, as these
data may be more relevant to real-life clinical settings. 
In conclusion, aripiprazole is an effective atypical antipsychotic and
therefore may be considered as a first-line agent. It may have
particular utility where tolerability is an issue, and may have particular
benefit in patients with mood-associated or negative symptoms.
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